



Blackline levels

In order for us to receive correct information regarding blackline levels and avoid confusion, particularly when requesting retrospective cumulative blacklined proofs, it is important that you understand our procedures and are aware of the real time status of a proof at any one time. The table below shows the history and status of this transaction and its blackline levels.

Notes

- 1. Unless instructed otherwise, we will automatically produce a new level of blacklining and sequentially change the proof number at each stage.
- 2. If a proof is submitted and further corrections are then received on the same day, it is important that you clearly define your blacklining requirements whether you want us to add to the latest level or produce a new level.
- 3. It is not possible to make corrections to a proof with a new level of blacklining but keep the proof number the same.

Proof No.	Blackline level	Date	CP	NP	Proof No.	Blackline level	Date	CP	NP
1	0	19.12.2025	–	–					
2	1	07.01.2026	9	–					
3	2	12.01.2026	7	–					
4	3	13.01.2026	5	–					
5	4	14.01.2026	2	–					

Clean proof

Job no.	272141
Proof no.	5
Date	14.01.2026

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION.

If you are in any doubt as to the action you should take, you are recommended to seek your own independent financial advice from a stockbroker, bank manager, solicitor, accountant, or other financial adviser authorised under the Financial Services and Markets Act 2000.

If you have sold or otherwise transferred all of your Ordinary shares in Polar Capital Global Healthcare Trust plc please send this Notice of Annual General Meeting, together with the accompanying documents, as soon as possible to the purchaser or transferee, or to the stockbroker, bank or other agent through whom the sale or transfer was effected, for delivery to the purchaser or transferee.

POLAR CAPITAL GLOBAL HEALTHCARE TRUST PLC

(incorporated and registered in England and Wales under number 07251471 and registered as an investment company under Section 833 of the Companies Act 2006)

NOTICE OF ANNUAL GENERAL MEETING ('AGM')

**to be held at 2.00 p.m. on Thursday, 26 February 2026 at the offices
of Polar Capital, 16 Palace Street, London, SW1E 5JD**



A form of proxy for Ordinary Shareholders is provided for use at the AGM. To be valid, the form of proxy should be completed and returned in accordance with the instructions thereon to Equiniti Limited at Aspect House, Spencer Road, Lancing, West Sussex, BN99 6DA as soon as possible but in any event so as to arrive not later than 48 hours before the time appointed for holding the meeting (excluding non-working days).

You are encouraged to complete and submit your form of proxy as soon as possible. Appointment of a proxy will not prevent you from attending and voting at the meeting if you subsequently find that you are able to do so.

Polar Capital Global Healthcare Trust plc

(incorporated and registered in England and Wales under number 07251471 and registered as an investment company under Section 833 of the Companies Act 2006)

Directors:

Lisa Arnold (Chair)
Neal Ransome (Audit Chair)
Caroline Gulliver (Audit Chair Elect)
Stacey Parrinder-Johnson
Jeremy Whitley

Registered Office:

16 Palace Street
London
SW1E 5JD

13 January 2026

Notice of the Fifteenth Annual General Meeting ('AGM') of Polar Capital Global Healthcare Trust plc (the 'Company')

Dear Shareholder

I have the pleasure in inviting Ordinary Shareholders to the Company's forthcoming Annual General Meeting ('AGM') which is being held at **2.00 p.m. on Thursday, 26 February 2026** at the offices of Polar Capital, 16 Palace Street, London, SW1E 5JD. Enclosed with this letter is your formal notice of AGM ('Notice of AGM') set out on pages 7 to 9 of this document and a form of proxy.

Following the success of the 2025 AGM, we have once again decided to separate the formal business of the AGM and the Portfolio Managers' investment update. We will therefore be holding the formal business in person (as per the requirements of the Articles of Association), which will require a quorum of members to be present at the meeting and will provide a recording of the Managers' 'Review of the Year and Outlook for the next year' on the Company's website ahead of the formal business meeting. Please note that the physical AGM will comprise the formal business and questions only; there will be no live Managers presentation. Shareholders will also be able to watch the proceedings of the AGM live via Zoom Conference.

Details of how to access the online link are provided below:

Meeting ID: 898 3411 0158

Passcode: 773407

Joining link: <https://polarcapital-co-uk.zoom.us/j/89834110158>

We are aware that many Shareholders are particularly interested in the components and performance of the Company's portfolio and therefore estimate that the Managers' presentation will be uploaded to the website on or before 12 February 2026 to give Shareholders time to consider the content ahead of the deadline to submit their proxy votes on the formal business. Once available, we will release a market announcement to invite shareholders and guests to listen to the recording and view the slides.

The Board believes that shareholder engagement remains important and is keen that the components of the AGM be participative for all. Shareholders are encouraged to listen to the recording, review the Managers' presentation and send any questions to the Managers and the Board via the Company Secretary at **cosec@polarcapital.co.uk** stating the subject matter as **PCGH-AGM**. Questions will be answered either directly or via the website. The AGM will be attended by the Board, including the Committee Chairs, and the Managers, all of whom will be available to respond to questions and concerns from Shareholders prior to and during the meeting.

All voting at the formal business meeting will be conducted on a Poll; you are therefore encouraged to submit your votes by proxy ahead of the meeting in accordance with the notes to the Notice of AGM on page 10. If you would like to vote on the resolutions on a Poll, but cannot attend the AGM, you can appoint a proxy to exercise all or any of your rights to attend, vote and speak at the AGM by using one of the methods set out in the notes to the Notice of AGM and noted on the reverse of the form of proxy.

The purpose of this letter is to explain the business to be considered at the AGM.

Resolution 1 – To receive the Annual Report and Financial Statements

The Annual Report and Financial Statements for the year ended 30 September 2025 will be presented to the AGM. The Annual Report accompanies this Notice of AGM or is available from the Company's website. Shareholders will be given an opportunity at the meeting to ask questions or can submit questions on the Annual Report and Financial Statements by email as detailed above.

Resolutions 2 & 3 – Directors' Remuneration Policy & Remuneration Implementation Report (pages 59 to 63 of the Annual Report)

Resolution 2 seeks Shareholder approval to renew the forward-looking Remuneration Policy which lasts for up to three years. The current Policy was approved by Shareholders at the 2023 AGM and will expire on 30 September 2026 unless renewed. The Policy being proposed has not changed from that which was approved in 2023 and if approved by Shareholders, the Remuneration Policy will remain in force until 30 September 2029.

Resolution 3 seeks approval, on an advisory basis, of the Remuneration Implementation Report, which looks back at the remuneration paid to the Directors for the year ended 30 September 2025.

Resolutions 4 to 8 – Election/Re-election of Directors

In accordance with the AIC Code of Corporate Governance, it is recommended that all Directors retire annually and, with the support of the Board, stand for election/re-election annually. Biographies of each of the Directors can be found on pages 6 and 7 of the Annual Report. The Board has confirmed its support and rationale for each Directors' election/re-election. The Directors believe that they have a balance of experience, expertise and sufficient diversity and that they work well together, each director brings multiple qualities and areas of expertise to the Board. The Board also considered the specific reasons why each Director's contribution is, and continues to be, important to the Company's long-term sustainable success, in accordance with the AIC Code, and these are set out below:

Lisa Arnold – Lisa has had an extensive career as a global pharmaceuticals and healthcare analyst ahead of her taking on non-executive director positions. Lisa brings a wealth of investment and strategic experience to the Board along with detailed and effective leadership skills, most recently demonstrated through the completion of the Company's recent tender offer process. Through Lisa's pension fund roles, particularly with the early adoption of TCFD, she has a comprehensive understanding of the importance and challenges of ESG and climate related issues. As Chair, Lisa has worked closely with the corporate brokers and the Managers to improve communication both internally and externally, especially from a shareholder perspective. Lisa continues to lead the Board with an inclusive and engaging manner and her nomination for re-election as Chair and non-executive Director is supported by both the Board and the Managers.

Neal Ransome – Neal has recent and relevant financial expertise with a strong accounting background which enables him to perform in-depth analyses of the Company's performance and Financial Statements. His extensive experience in evaluating pharmaceutical and healthcare companies, having previously led PwC's Pharmaceutical and Healthcare M&A practice, further enhances his qualifications. Neal serves as the Chair of the Company's Audit Committee, a role in which he has had extensive experience from prior board roles. Neal's re-election as a non-executive Director is supported by the Board and the Managers; Neal will hand over the Chair of the Audit Committee to Caroline Gulliver and the Chair of the Management Engagement Committee to Lisa Arnold with effect from the close of the AGM to be held in February 2026.

Caroline Gulliver – The Board elected to appoint Caroline as a non-executive Director following a recruitment process which took place during the course of the year, resulting in her appointment on 15 May 2025. Caroline's election will be proposed to shareholders at the AGM; subject to approval, Caroline will assume the role of Chair of the Audit Committee with effect from the conclusion of the AGM. Caroline has had a strong start to her board tenure and the Board support her formal election by Shareholders.

Stacey Parrinder-Johnson – The Board elected to appoint Stacey as a non-executive Director following a recruitment process which took place during the course of the year, resulting in her appointment on 1 July 2025. Stacey's election will be proposed to shareholders at the AGM. Stacey has brought a new and informative perspective to board discussions, and the Board support her formal election by Shareholders.

Jeremy Whitley – Jeremy’s extensive experience, particularly from his previous roles at Aberdeen Asset Management, has equipped him with a global perspective and the ability to critically review the portfolio. He has been a strong advocate for clear performance attribution analysis. Additionally, Jeremy brings valuable experience from other investment trust management houses to the Board. Jeremy’s re-election as a non-executive Director is supported by the Board and the Managers.

Resolutions 9 & 10 – Re-appointment of Auditors and Auditors’ Remuneration

There is a requirement to appoint an auditor at each general meeting at which accounts are laid before the Company, with the expectation that the auditor will then hold office until the next such meeting. Shareholders are required to approve the appointment of the Company’s auditor each year and to determine or authorise the Directors to determine the auditor’s remuneration. **Resolution 9** relates to the re-appointment of PricewaterhouseCoopers LLP as the Company’s independent auditors to hold office until the next AGM of the Company and **Resolution 10** authorises the Directors to determine their remuneration.

Resolution 11 – Dividend Policy

The Company’s dividend policy remains that dividends will be paid bi-annually in February and August. Given the Company’s focus on capital growth, the policy may at times result in lower dividends being paid in future than historically. The interim dividends will not necessarily be of equal amounts because the dividends from the Company’s underlying investments are expected to arrive irregularly throughout the financial year. Shareholders should recognise that circumstances may arise when it is necessary to reduce the level of dividend payment or equally there may be instances when the level of dividend must be increased in order to comply with Sections 1158 and 1159 of the Corporation Tax Act 2010. Where this would result in paying a dividend beyond the Board’s intended policy a ‘special dividend’ will be declared and paid.

Resolutions 12 & 13 – Allotment of Shares

Resolution 12 deals with the Directors’ authority to allot Ordinary Shares. At last year’s AGM, the Directors were given authority to allot Ordinary Shares in the capital of the Company up to a maximum nominal amount of £3,031,750 representing approximately 10 per cent. of the Company’s issued Ordinary share capital. Resolution 12 will, if passed, renew the authority to allot given to the Directors at last year’s AGM on similar terms in respect of 12,414,924 Ordinary shares with a nominal amount of £3,103,731 representing approximately 10 per cent. of the Company’s issued Ordinary share capital (i.e. including shares held in treasury) on 6 January 2026. The authority will continue until the end of the next AGM of the Company.

As a result of shares bought back as part of the Tender Offer in November 2025, the Company is also seeking additional authority under **Resolution 13** to allot Ordinary Shares in the capital of the Company up to a maximum nominal amount of £3,103,731 representing approximately 10 per cent. of the Company’s issued Ordinary share capital. This authority will only be utilised once the authority outlined within Resolution 12 has been exhausted.

Resolutions 14 & 15 – Disapplication of Statutory Pre-emption Rights

Resolution 14 will give the Directors power to allot Ordinary shares pursuant to the authorities granted under Resolutions 12 for cash without, in certain circumstances, being required to comply with the pre-emption rights in the Companies Act 2006. In particular, this power will permit the Directors to allot Ordinary shares up to a maximum nominal value of £3,103,731, representing approximately 10 per cent. of the issued Ordinary share capital of the Company (i.e. including shares held in treasury) as at 6 January 2026, for cash otherwise than in connection with an offer to existing Shareholders. This authority also permits the Directors to re-sell the shares held in treasury. The authority conferred by Resolution 14 will expire upon the expiry of the general authority conferred in Resolution 12.

Resolution 15 will give Directors an additional authority to allot Ordinary shares up to a maximum nominal value of £3,103,731, representing approximately 10 per cent. of the issued Ordinary share capital of the Company (i.e. including shares held in treasury) as at 6 January 2026. This authority will only be utilised once the authority outlined within Resolution 14 has been exhausted and will expire upon the expiry of the general authority conferred in Resolution 13.

The Directors' policy on the issue of new Ordinary shares is for the net issue price (after an allocation of costs) to be above the Net Asset Value ('NAV') per share. Any re-issue of shares from treasury will follow institutional guidelines but it is not anticipated that such shares would be re-issued at prices below NAV.

The Directors consider that renewing the Company's share allotment authority and disapplying pre-emption rights in respect of allotment of new shares is advantageous for Shareholders on the basis that (a) any new Ordinary shares issued for cash will be at a price that will be in excess of NAV and should therefore enhance NAV for existing Shareholders (over the longer term); (b) a larger capital base should result in a lower ongoing charges ratio for the Company because of the fixed element of cost; and (c) the increased number of Ordinary shares should improve their liquidity. The Directors further believe that having the ability to ensure a ready supply of Ordinary shares to the market should assist in avoiding the creation of an excessive and unsustainable premium over NAV, which could increase the risks for new investors.

Since the AGM in February 2025, and up to close of business on 6 January 2026, the Company has issued 525,000 ordinary shares.

Resolution 16 – Authority to Make Market Purchases of Ordinary Shares

Resolution 16 renews the authority granted to the Company to buy back its own Ordinary shares in the market as permitted by the Companies Act 2006.

The Company was given authority to make market purchases of up to 14.99 per cent. of the Company's Ordinary share capital at last year's AGM. Your Board wishes to renew this authority so that the Company will retain the flexibility to make market purchases of its own shares where your Board considers it desirable to do so.

If Resolution 16 is passed, the Company may opt to cancel or hold in treasury all of the Ordinary shares it may purchase pursuant to the authorities contained therein.

During the year ended 30 September 2025, no shares were bought back. Following the year end, the Company bought back 27,253,026 ordinary shares into treasury as part of the tender offer to shareholders in November 2025. As at 6 January 2026, the Company held 29,607,282 ordinary shares in treasury.

The Directors believe that to make such purchases of Ordinary shares in the market at appropriate times and prices is a suitable method of enhancing Shareholder value. Where the purchases of Ordinary shares are made at prices below the prevailing NAV per share, this will enhance the net asset value for the remaining Shareholders. The Board therefore intends that purchases of Ordinary shares would only be made at prices below the NAV.

The Company would, within guidelines set from time to time by the Board, make either a single purchase or a series of purchases, when market conditions are suitable, with the aim of maximising the benefits to Shareholders. The Board considers that it will be most advantageous to Shareholders for the Company to be able to make such purchases as and when it considers market conditions to be favourable and therefore does not propose to set a timetable for making any such purchases.

Resolution 16 provides that the number of Ordinary shares that could be purchased does not exceed a maximum of 18,609,973 (representing approximately 14.99 per cent. of the Company's issued Ordinary share capital as at 6 January 2026, or such other number representing 14.99 per cent of the issued ordinary share capital, including treasury shares, at the date of the meeting). The resolution also sets the maximum price that may be paid by the Company at the higher of 105 per cent. of the average middle-market quotation for an Ordinary share on the 5 business days immediately preceding the date of the relevant purchase or the higher of the last independent trade and the highest independent bid. The minimum price to be paid will be 25p per Ordinary share (being the nominal value per share).

The authority granted under Resolution 16 will last until the end of the next AGM of the Company or until the whole of the 14.99 per cent. has been utilised, whichever is the earlier.

Under the Companies Act 2006, the Company is allowed to hold its own Ordinary shares in treasury following a buy back, instead of cancelling them. This gives the Company the ability to re-sell treasury shares quickly and cost effectively and provides the Company with additional flexibility in the management of its

capital base. Shares held in treasury have their voting and dividend rights suspended. If the Directors exercise the authority conferred by Resolution 16 the Company will have the option of either cancelling or holding in treasury any of its own Ordinary shares purchased in the market. The Directors will decide at the time of purchase which option to pursue. The Directors will have regard to any guidelines issued by investor groups at the time of any such purchase with respect to the holding for resale of treasury shares.

Recommendation

The Notice of AGM is set out at the end of this document.

Your Board believes that the passing of the Resolutions should help to promote the success of the Company and is in the best interests of the Company and its Shareholders as a whole. The Directors unanimously recommend that you vote in favour of the resolutions as they intend to do in respect of their own beneficial holdings which amount to 84,823 shares representing approximately 0.09 per cent. of the total voting rights of the issued Ordinary share capital of the Company (excluding shares held in treasury).

If you are an ordinary shareholder, we recommend you complete your form of proxy to ensure your votes are counted in the Poll vote for each resolution. If you would like to vote on the resolutions on the Poll at the meeting but cannot come to the AGM, you can appoint a proxy to exercise all or any of your rights to attend, vote and speak at the AGM by using one of the methods set out in the notes to the notice of AGM. You are therefore urged to return the provided form of proxy without delay.

Yours sincerely

Lisa Arnold
Chair

13 January 2026

NOTICE OF ANNUAL GENERAL MEETING

Polar Capital Global Healthcare Trust plc

(incorporated and registered in England and Wales under number 07251471 and registered as an investment company under Section 833 of the Companies Act 2006)

NOTICE IS HEREBY GIVEN that the Fifteenth Annual General Meeting ('AGM') of the Company will be held at 2.00 p.m. on Thursday, 26 February 2026 at the offices of Polar Capital, 16 Palace Street, London, SW1E 5JD, to consider and, if thought fit, to pass Resolutions 1 to 13 as **Ordinary Resolutions** (which require a majority in excess of 50 per cent. to be passed) and to consider and, if thought fit, pass resolutions 14 to 16 as **Special Resolutions** (which require a majority of at least 75 per cent. to be passed).

AS ORDINARY RESOLUTIONS

Annual Report and Financial Statements

1. To receive and consider the Annual Report and Financial Statements for the year ended 30 September 2025.

Directors' Remuneration Policy & Remuneration Implementation Report

2. To receive and approve the Directors' Remuneration Policy contained in the Report on Directors' Remuneration, such approval to begin from the expiry of the current Policy on 30 September 2026 and last until 30 September 2029 unless the approval is renewed prior to such time.
3. To receive and approve the Directors' Remuneration Implementation Report for the year ended 30 September 2025.

Election/Re-election of Directors

4. To re-elect Lisa Arnold as a Director of the Company.
5. To re-elect Neal Ransome as a Director of the Company.
6. To elect Caroline Gulliver as a Director of the Company.
7. To elect Stacey Parrinder-Johnson as a Director of the Company.
8. To re-elect Jeremy Whitley as a Director of the Company.

Re-appointment of Auditors and Auditors' Remuneration

9. To re-appoint PricewaterhouseCoopers LLP as auditors to the Company to hold office until the conclusion of the next AGM of the Company.
10. To authorise the Directors to determine the remuneration of the auditors.

Dividend Policy

11. To approve the Company's Dividend Policy.

Allotment of Shares – First Authority

12. **THAT** the Directors be and they are hereby generally and unconditionally authorised pursuant to section 551 of the Companies Act 2006 (the 'Act'), and in substitution for all existing authorities, to exercise all powers of the Company to allot shares in the Company up to a maximum aggregate nominal amount of £3,103,731 (being 10 per cent. of the Company's issued Ordinary share capital, including treasury shares, on 6 January 2026 or, if changed, the number representing 10 per cent. of the issued share capital of the Company at the date the resolution is passed) **PROVIDED THAT** this

authority shall expire at the conclusion of the next AGM of the Company after the passing of this resolution, save that the said authority shall allow and enable the Directors to make an offer or agreement before the expiry of that authority which would or might require relevant securities to be allotted after such expiry and the Directors may allot relevant securities in pursuance of such an offer or agreement as if the authority conferred hereby had not expired.

Allotment of Shares – Second Authority

13. **THAT** the Directors be and they are hereby generally and unconditionally authorised pursuant to section 551 of the Companies Act 2006 (the 'Act'), and in substitution for all existing authorities, to exercise all powers of the Company to allot shares in the Company up to a maximum aggregate nominal amount of £3,103,731 (being 10 per cent. of the Company's issued Ordinary share capital, including treasury shares, on 6 January 2026 or, if changed, the number representing 10 per cent. of the issued share capital at the date the resolution is passed) **PROVIDED THAT** this authority shall expire at the conclusion of the next AGM of the Company after the passing of this resolution, save that the said authority shall allow and enable the Directors to make an offer or agreement before the expiry of that authority which would or might require relevant securities to be allotted after such expiry and the Directors may allot relevant securities in pursuance of such an offer or agreement as if the authority conferred hereby had not expired.

AS SPECIAL RESOLUTIONS

Disapplication of Statutory Pre-emption Rights – First Authority

14. **THAT**, subject to the passing of Resolution 12, the Directors be and they are hereby empowered pursuant to Section 570 and Section 573 of the Act to allot equity securities (within the meaning of Section 560 of the Act) wholly for cash pursuant to the authority conferred by Resolution 12 and/or sell shares held by the Company as treasury shares for cash as if sub-section (1) of Section 561 of the Act did not apply to any such allotment **PROVIDED THAT** this power shall be limited:
- (i) to the allotment of equity securities and sale of treasury shares for cash whether by way of a rights issue, open offer or otherwise to Ordinary Shareholders and/or holders of any other securities in accordance with the rights of those securities where the equity securities respectively attributable to the interests of all Ordinary Shareholders and/or such holders are proportionate (or as nearly as may be) to the respective numbers of Ordinary shares and such equity securities held by them (or as otherwise allotted in accordance with the rights attaching to such equity securities) subject in either case to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or legal or practical problems arising under the laws of any overseas territory or the requirements of any regulatory body or stock exchange or any other matter whatsoever; and
 - (ii) to the allotment (otherwise than pursuant to sub-paragraph (i) above) of equity securities up to a maximum aggregate nominal value of £3,103,731 (being 10 per cent. of the Company's issued Ordinary share capital, including treasury shares, on 6 January 2026 or, if changed, the number representing 10 per cent. of the issued share capital of the Company at the date the resolution is passed);

and this power shall expire at the conclusion of the next AGM of the Company after the passing of this resolution, save that the Directors may before such expiry make an offer or agreement which would or might require equity securities to be allotted after such expiry and the Directors may allot securities in pursuance of such an offer or agreement as if the power conferred hereby had not expired.

Disapplication of Statutory Pre-emption Rights - Second authority

15. **THAT** subject to the passing of Resolution 13 above, and in substitution for any existing power the Directors be and they are hereby empowered pursuant to Section 570 and Section 573 of the Act to allot equity securities (within the meaning of Section 560 of the Act) wholly for cash pursuant to the authority conferred by Resolution 13 and/or sell shares held by the Company as treasury shares for cash as if sub-section (1) of Section 561 of the Act did not apply to any such allotment **PROVIDED THAT** this power shall be limited:

- (i) to the allotment of equity securities and sale of treasury shares for cash whether by way of a rights issue, open offer or otherwise to Ordinary Shareholders and/or holders of any other securities in accordance with the rights of those securities where the equity securities respectively attributable to the interests of all Ordinary Shareholders and/or such holders are proportionate (or as nearly as may be) to the respective numbers of Ordinary shares and such equity securities held by them (or as otherwise allotted in accordance with the rights attaching to such equity securities) subject in either case to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or legal or practical problems arising under the laws of any overseas territory or the requirements of any regulatory body or stock exchange or any other matter whatsoever; and
- (ii) to the allotment (otherwise than pursuant to sub-paragraph (i) above) of equity securities up to a maximum aggregate nominal value of £3,103,731 (being 10 per cent. of the Company's issued Ordinary share capital, including treasury shares, on 6 January 2026 or, if changed, the number representing 10 per cent. of the issued share capital of the Company at the date the resolution is passed);

and this power shall expire at the conclusion of the next AGM of the Company after the passing of this resolution, save that the Directors may before such expiry make an offer or agreement which would or might require equity securities to be allotted after such expiry and the Directors may allot securities in pursuance of such an offer or agreement as if the power conferred hereby had not expired.

Authority to buy back shares

16. **THAT** the Company be and is hereby generally and unconditionally authorised pursuant to Section 701 of the Act to make market purchases (within the meaning of Section 693 of the Act) of Ordinary shares of 25p each in the capital of the Company, on such terms and in such manner as the Directors may from time to time determine **PROVIDED THAT:**

- (i) the maximum number of Ordinary shares hereby authorised to be purchased shall be 18,609,973; representing approximately 14.99 per cent. of the issued share capital, including treasury shares, at 6 January 2026 or, if changed, the number representing 14.99 per cent of the issued share capital of the Company at the date the resolution is passed;
- (ii) the minimum price excluding expenses which may be paid for an Ordinary share is 25p;
- (iii) the maximum price excluding expenses payable by the Company for each Ordinary share is the higher of:
 - (a) 105 per cent. of the average of the middle-market quotations of the Ordinary shares for the five business days prior to the date of the market purchase; and
 - (b) the higher of the price of the last independent trade and the highest current independent bid for an Ordinary share on the trading venues where the market purchases by the Company pursuant to the authority conferred by this Resolution 16 will be carried out.
- (iv) the Company may make a contract to purchase Ordinary shares under the authority hereby conferred prior to the expiry of such authority which will or may be executed wholly or partly after the expiration of such authority and may make a purchase of Ordinary shares pursuant to any such contract; and
- (v) any Ordinary shares so purchased shall be:
 - (a) cancelled immediately upon completion of the purchase; or
 - (b) held, sold, transferred or otherwise dealt with as treasury shares in accordance with the provisions of the Companies Act 2006.

BY ORDER OF THE BOARD

Tracey Lago, FCG
Polar Capital Secretarial Services Limited
Company Secretary

13 January 2026

16 Palace Street
 London
 SW1E 5JD

Notes to the Notice of Annual General Meeting

1. Only those ordinary shareholders registered in the register of members of the Company at close of business on 24 February 2026 (or, if the AGM (the 'Meeting') is adjourned, close of business on the day which is two working days prior to any adjourned Meeting) shall be entitled to attend, speak and vote at the Meeting in respect of the number of shares registered in their name at that time. Changes to entries on the relevant register of securities after 24 February 2026 will be disregarded in determining the rights of any person to attend or vote (and the number of votes they may cast) at the Meeting or any adjourned Meeting.

2. An ordinary shareholder entitled to attend, speak and vote at the Meeting may appoint one or more proxies (who need not be a member of the Company) to exercise all or any of his or her rights to attend, speak and vote at the Meeting. An ordinary shareholder can appoint more than one proxy in relation to the meeting provided that each proxy is appointed to exercise the rights attaching to different shares held by the ordinary shareholder. If two or more valid proxy forms are delivered or received in respect of the same share for use at the same Meeting, the one which was last sent shall be treated as replacing and revoking the others in their entirety.

If the Company is unable to determine the one which was last sent, the one which is last received shall be so treated. If the Company is unable to determine either which is last sent or which is last received, none of them shall be treated as valid in respect of that share. Voting on all resolutions will be conducted on a Poll. Every ordinary shareholder who is present in person at a general meeting of the Company, and every person (not being himself or herself a member entitled to vote) who is present as proxy for a member entitled to vote, shall have one vote for every share held by him or her.

3. A proxy does not need to be a member of the Company but must attend the Meeting to represent you. Your proxy could be the Chair, another Director of the Company or another person who has agreed to attend to represent you. Your proxy will vote as you instruct and must attend the meeting for your vote to be counted. Details of how to appoint the Chair or another person as your proxy using the proxy form are set out in the notes to the proxy form. Appointing a proxy does not preclude you from attending the Meeting and voting in person.
4. A form of proxy is enclosed. To be valid the form of proxy must be completed and delivered (together with any authority under which it is executed or a copy of the authority certified notially or in some other way approved by the Directors) to the office of the Registrar to the Company not less than 48 hours before the time appointed for holding the Meeting (excluding non-working days). The form of proxy should be returned to Equiniti Limited at the address given on the proxy form.

The return of the form of proxy duly completed will not preclude a member from attending, speaking and voting in person at the Meeting. CREST members who wish to appoint a proxy or proxies by utilising the CREST electronic proxy appointment service may do so by utilising the procedures described in the CREST Manual which can be viewed at www.euroclear.co.uk. CREST Personal Members or other CREST sponsored members, and those CREST members who have appointed a voting service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf. In order for a proxy appointment made by means of CREST to be valid. The appropriate CREST message (a 'CREST Proxy Instruction') must be properly authenticated in accordance with Euroclear UK & Ireland Limited's (EUI) specifications and

must contain the information required for such instructions, as described in the CREST Manual. The message, regardless of whether it constitutes the appointment of a proxy or an amendment to the instruction given to a previously appointed proxy must, in order to be valid, be transmitted so as to be received by the Company's agent (ID number RA19) by not later than 48 hours before the time appointed for the holding of the meeting (excluding non-working days i.e. by 2.00 p.m. on 24 February 2026).

For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp applied to the message by the CREST Applications Host) from which the Company's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5) (a) of the Uncertificated Securities Regulations 2001.

5. If you are an institutional investor you may be able to appoint a proxy electronically via the Proxymity platform, a process which has been agreed by the Company and approved by the Registrar. For further information regarding Proxymity, please go to www.proxymity.io. Your proxy must be lodged by 2.00 p.m. on 24 February 2026 in order to be considered valid. Before you can appoint a proxy via this process you will need to have agreed to Proxymity's associated terms and conditions. It is important that you read these carefully as you will be bound by them and they will govern the electronic appointment of your proxy.
6. The attendance at the Meeting of members and their proxies and representatives is understood by the Company to confirm their agreement to receive any communications made at the Meeting.
7. Electronic Proxy Appointment ('EPA') is available for this Annual General Meeting ('AGM'). To appoint a proxy electronically log into the Company's Registrars' online portfolio service, Shareview. You can submit your proxy by logging on to your portfolio at www.shareview.co.uk using your usual user ID and password. Once logged in simply click 'View' on the 'My Investments' page, click on the link to vote then follow the on screen instructions. EPA will not be valid if received after 2.00 p.m. on 24 February 2026 or if the AGM is adjourned, 48 hours before the time for holding the adjourned AGM (excluding non-working days), and will not be accepted if found to contain a computer virus.
8. To change your proxy instructions, you may return a new proxy appointment using the methods set out above. Where you have appointed a proxy using the hard copy form of proxy and would like to change the instructions using another hard copy form of proxy, please contact Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex, BN99 6DA. The deadline for receipt of proxy appointments (see above) also applies in relation to amended instructions. Where two or more valid separate appointments of proxy are received in respect of the same share in respect of the same meeting, the one which is last sent shall be treated as replacing and revoking the other or others.
9. As at the date of this Notice, the Company's issued share capital consists of 124,149,256 ordinary shares of 25p each. The Company holds 29,054,256 ordinary shares in treasury. Therefore, the total voting rights in the Company is 95,095,000.
10. A copy of this notice has been sent for information only to persons who have been nominated by a member to enjoy information rights under section 146 of the Companies Act 2006 (a 'Nominated Person'). The rights to appoint a proxy cannot be exercised by a Nominated Person: they can only be exercised by the member. However, a Nominated Person

may have a right under an agreement between him and the member by whom he was nominated to be appointed as a proxy for the Meeting or to have someone else so appointed. If a Nominated Person does not have such a right or does not wish to exercise it, he may have a right under such an agreement to give instructions to the member as to the exercise of voting rights.

11. A member of the Company which is a corporation may authorise a person or persons to act as its representative(s) at the AGM. In accordance with the provisions of the Companies Act 2006, each such representative may exercise (on behalf of the corporation) the same powers as the corporation could exercise if it were an individual member of the Company, provided that they do not do so in relation to the same shares. It is no longer necessary to nominate a designated corporate representative.
12. Pursuant to section 319A of the Companies Act 2006, the Company must cause to be answered at the Meeting any question relating to the business being dealt with at the Meeting which is put by a member attending the meeting, except in certain circumstances, including if it is undesirable in the interests of the Company or the good order of the meeting that the question be answered or if to do so would involve the disclosure of confidential information.
13. Members satisfying the thresholds in section 527 of the Companies Act 2006 can require the Company to publish a statement on its website setting out any matter relating to: (a) the audit of the Company's accounts (including the auditor's report and the conduct of the audit) that are to be laid before the Meeting; or (b) any circumstance connected with an auditor of the Company ceasing to hold office since the last AGM, that the members propose to raise at the Meeting. The Company cannot require the members requesting the publication to pay its expenses. Any statement placed on the website must also be sent to the Company's auditors no later than the time it makes its statement available on the website. The business which may be dealt with at the meeting includes any statement that the Company has been required to publish on its website.
14. In accordance with section 311A of the Companies Act 2006, the contents of this notice of meeting, details of the total number of shares in respect of which members are entitled to exercise voting rights at the AGM and, if applicable, any members' statements, members' resolutions or members' matters of business received by the Company after the date of this notice will be available on the Company's website: www.polarcapitalglobalhealthcaretrust.co.uk
15. The terms of appointment of the Directors are available for inspection at the registered office of the Company during usual business hours (Saturdays, Sundays and public holidays excepted) and will be available at the place of the Meeting from 1.30 p.m. until its conclusion.
16. You may not use any electronic address provided either in this Notice of AGM or any related documents (including the form of proxy) to communicate with the Company for any purposes other than those expressly stated.
17. Please note that the Company takes all reasonable precautions to ensure no viruses are present in any electronic communication it sends out but the Company cannot accept responsibility for loss or damage arising from the opening or use of any email or attachments from the Company and recommends that the Shareholders subject all messages to virus checking procedures prior to use. Any electronic communication received by the Company, including the lodgement of an electronic proxy form, that is found to contain any virus will not be accepted.

18. To be able to exercise the members' right to require:
 - (i) circulation of a resolution to be proposed to the AGM; or
 - (ii) a matter of business to be dealt with at the AGM; The relevant request must be made by:
 - (a) a member or members having the right to vote at the AGM and holding at least 5 per cent. of the total voting rights of the Company; or
 - (b) at least 100 members having the right to vote at the AGM and holding, on average, at least £100 of paid up share capital.

For information on voting rights, including the total number of voting rights in the Company see above note [9].

19. Where a member or members wish to request the Company to:
 - (i) circulate a resolution to be proposed to the AGM; or
 - (ii) a matter of business to be dealt with at the AGM;

Such request must be made in accordance with one of the following:

- (a) a hard copy request signed by you stating your full name and address and providing evidence of the number of shares held sent to the Company Secretary, Polar Capital Global Healthcare Trust Plc, 16 Palace Street, London, SW1E 5JD.
 - (b) a scanned copy of a request signed by you stating your full name and address and providing evidence of the number of shares held sent to **cosec@polarcapital.co.uk**, stating **PCGH AGM** in the subject field.
 - (c) a request signed by you stating your full name and address and providing evidence of the number of shares held sent by fax to 020 7227 2799, marked for the attention of the Company Secretary, Polar Capital Global Healthcare Trust Plc and stating **PCGH AGM** in the subject field.
20. Under section 360BA of the Companies Act 2006, a member may, subject to conditions, request confirmation that their vote on a resolution at a general meeting where a Poll has been taken has been validly recorded and counted.

The conditions are that:

- (a) the member makes a request for the information which is received by the Company no later than 30 days from the date of the AGM; and
- (b) the member does not have any other reasonable means by which to determine that their vote has been validly recorded and counted by the Company.

Upon receipt of the request, the Company must provide the information to the member as soon as reasonably practicable and in any event by the end of the period of 15 days beginning with whichever is the later of the first working day after the day on which:

- (a) the result of the Poll is declared for that resolution; or
- (b) the request for information under subsection (a) is received by the Company.

Polar Capital Global Healthcare Trust plc
(incorporated and registered in England and Wales, registered number 07251471,
as an investment company within the meaning of Section 833 of the Companies Act 2006)

Registered office: 16 Palace Street, London SW1E 5JD

Perivan.com
272141